Annual Report Summary

Overview

The report highlights 2022 revenue of RMB 30,365.64 million, total profit of RMB 10,953.55 million and 20.17% year-on-year revenue growth. It describes the Company's three core businesses—Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging Systems—and their continued expansion. R&D expenditure reached RMB 3,190.97 million, up 17.06% year on year.

Document

Report type: Annual Report
Class: Financial
Scope: Extract
Fiscal year: 2022
Period: Ends 31 December 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services